NCT01730118View on ClinicalTrials.gov

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 4, 2013

Primary Completion Date

December 3, 2019

Study Completion Date

December 3, 2019

Conditions
Breast NeoplasmsBreast CancerAdenocarcinomasMetastatic Solid Tumors Characterized by HER2/Neu Expression
Interventions
BIOLOGICAL

Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine

autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01730118 - Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Biotech Hunter | Biotech Hunter